MSB Trading - 2020, page-12821

Your usual cockeyed maths Sector.

You got that 200 Temcell patients per year from a calculation I did for you elsewhere in answer to a question from you. It was my own guess and based on total royalties received, factoring into the calculation the royalty percentage and price per treatment. I explained that to you. I've never seen a company published figure.

My calculation could be wrong but that's not the important thing. You completely ignore what you were also told, namely that patients are doubling year on year. That is far more important. Temcell cures a condition that CYP has done a n=9 phase1 trial 2 years ago and nothing since. The number per year, be it 200 or anything else, is a calculation averaged over 4 years, following the usual gradual uptake. Over the past 12 months it would be a whole lot greater than that. And doubling, get it?

I'll never understand the mindset of someone who gets such pleasure from any hint of reversal in a company for which your stumbling pet, CYP, is not even a competitor. Your vain hope is to elevate CYP's standing by pulling down MSB. It won't work.

That temporary manufacturing hitch in Japan is possibly costing children's lives. You do have peculiar satisfactions.